BRAIN and NERVE－神経研究の進歩75巻7号

2023年07月発行

特集 Antibody Update 2023　Part2 末梢編

ギラン・バレー症候群—日常診療での自己抗体の意義

著者： 古賀道明¹

所属機関： ¹山口大学大学院医学系研究科臨床神経学

ページ範囲：P.807 - P.812

文献概要

自己抗体の測定は，ギラン・バレー症候群（Guillain-Barré Syndrome：GBS）やフィッシャー症候群の診療に欠かせない検査となった。しかし，実際に測定される抗体は種類が非常に多く，感度や特異度は必ずしも十分ではない。さらに検出される抗体の意義は抗体ごとに異なっている。特に脱髄型GBSでは診断マーカーとして確立した自己抗体は未同定であり，検査の限界を理解していないと，検査結果が診断をミスリードしかねないことに留意すべきである。

参考文献

1）Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, et al: Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 23: 440-447, 1988

2）Kusunoki S, Willison HJ, Jacobs BC: Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. J Neurol Neurosurg Psychiatry 92: 311-318, 2021

3）海田賢一, 楠 進：自己免疫性ニューロパチーと抗糖脂質抗体. Brain Nerve 65：413-423, 2013

4）Goodfellow JA, Willison HJ: Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol 29: 572-580, 2016

依存性糖脂質抗体. Brain Nerve 70：405-417, 2018

6）森 雅裕：脱髄型ギラン・バレー症候群の標的分子. Brain Nerve 67：1359-1369, 2015

7）Yako K, Kusunoki S, Kanazawa I: Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci 168: 85-89, 1999

8）Susuki K, Yuki N, Hirata K, Kuwabara S: Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. J Neurol Sci 195: 145-148, 2002

9）Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I: Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 18: 409-413, 1995

10）Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Roodbol J, Hoogenboezem T, et al: Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: a case-control study. Ann Neurol 80: 566-580, 2016

11）Samukawa M, Hamada Y, Kuwahara M, Takada K, Hirano M, et al: Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody. J Neurol Sci 337: 55-60, 2014

12）Susuki K, Odaka M, Mori M, Hirata K, Yuki N: Acute motor axonal neuropathy after Mycoplasma infection: evidence of molecular mimicry. Neurology 62: 949-956, 2004

13）Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, et al: Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 68: 19-26, 1996

14）Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG: Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 62: 641-643, 1997

15）Yuki N, Tagawa Y: Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 154: 14-17, 1998

16）Sawai S, Satoh M, Mori M, Misawa S, Sogawa K, et al: Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 83: 113-117, 2014

17）Miyaji K, Devaux J, Yuki N: Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 83: 2314-2315, 2014

18）Mathey EK, Pollard J: Myelin antigens in Guillain-Barré syndrome: EAN, the pied piper of myelin. In: Willison HJ, Goodfellow JA, Hughes RAC, Asbury AK: GBS 100: Celebrating a century of progress in Guillain-Barré syndrome. Peripheral Nerve Society, San Diego, 2016, pp418-422

19）Willison HJ, Jacobs BC, van Doorn PA: Guillain-Barré syndrome. Lancet 388: 717-727, 2016

20）Prüss H, Schwab JM, Derst C, Görtzen A, Veh RW: Neurofascin as target of autoantibodies in Guillain-Barré syndrome. Brain 134: e173, 2011［doi: 10.1093/brain/awq372］

21）Devaux JJ, Odaka M, Yuki N: Nodal proteins are target antigens in Guillain-Barré syndrome. J Peripher Nerv Syst 17: 62-71, 2012

22）Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, et al: Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79: 2241-2248, 2012

23）Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, et al: Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138: 1484-1491, 2015

24）Doppler K, Appeltshauser L, Villmann C, Martin C, Peles E, et al: Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139: 2617-2630, 2016

25）Appeltshauser L, Brunder AM, Heinius A, Körtvélyessy P, Wandinger KP, et al: Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm 7: e817, 2020［doi: 10.1212/NXI.0000000000000817］

26）Zhao N, Chang SH, Zhang QX, Zhang LJ, Jiang SM, et al: Clinical features of Guillain-Barré syndrome with anti-neurofascin 155 antibody. Acta Neurol Scand 146: 553-561, 2022

27）古賀道明：慢性炎症性脱髄性多発ニューロパチーの自己抗体. Brain Nerve 70：395-403, 2018

28）Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, et al: European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst 26: 242-268, 2021

29）Koga M, Takahashi M, Yokoyama K, Kanda T: Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants. J Neurol 262: 1954-1960, 2015

30）国分則人：ギラン・バレー症候群の神経生理. Brain Nerve 67：1321-1328, 2015